In 1-2 punch, Mol­e­c­u­lar Tem­plates cuts first-gen can­di­date and los­es a Big Phar­ma part­ner; Charles Riv­er teams up with Va­lence to pro­vide AI dis­cov­ery plat­form

It’s been sev­er­al months since a treat­ment-re­lat­ed death led the FDA to put a par­tial hold on Mol­e­c­u­lar Tem­plates’ on­ly first-gen­er­a­tion en­gi­neered tox­in body …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER